Infectious Disease Diagnostics Market Overview
The global infectious disease diagnostics market is projected to expand at a CAGR of approximately 7% over the next five years, supported by the increasing global burden of infectious diseases and the growing need for rapid, reliable, and accessible diagnostic solutions. The continued emergence of viral, bacterial, fungal, and parasitic infections is increasing the demand for technologies capable of identifying pathogens at an early stage and supporting timely clinical intervention.
The growing threat of emerging and re-emerging infectious diseases is also encouraging healthcare organizations and governments to strengthen diagnostic infrastructure. Outbreaks of respiratory infections, antimicrobial-resistant pathogens, and other communicable diseases have highlighted the importance of rapid pathogen identification, disease surveillance, and effective infection-control strategies. As a result, healthcare providers are increasingly adopting advanced diagnostic platforms across hospitals, laboratories, clinics, and decentralized care settings.
Key Request a free sample copy or view report summary: https://meditechinsights.com/infectious-disease-diagnostics-market/request-sample/
The market is further benefiting from increasing demand for point-of-care (POC) testing. Rapid diagnostic technologies enable healthcare professionals to obtain actionable results closer to the patient, reducing dependence on centralized laboratories and shortening the time between testing and treatment. This is particularly important in emergency care, rural healthcare facilities, pharmacies, outpatient settings, and locations with limited laboratory infrastructure.
Technological innovation is another important factor shaping market development. Molecular diagnostics, polymerase chain reaction (PCR), next-generation sequencing (NGS), immunodiagnostics, automated microbiology systems, and other advanced platforms are improving the sensitivity, specificity, speed, and scalability of infectious disease testing. Integration with digital health platforms, laboratory information systems, artificial intelligence, and data analytics is also creating new opportunities for more efficient disease surveillance and clinical decision-making.
How Is the Infectious Disease Diagnostics Market Evolving?
The infectious disease diagnostics market comprises a broad range of tests, instruments, reagents, kits, consumables, and software used to identify infectious pathogens and support disease management. These solutions are designed to detect viruses, bacteria, fungi, and parasites across hospitals, diagnostic laboratories, physician offices, point-of-care settings, research institutions, and public health organizations.
Diagnostic approaches within the market include molecular assays, antigen and antibody-based immunodiagnostics, microbiological culture, sequencing technologies, and rapid diagnostic tests. Each technology addresses different clinical and public health requirements, ranging from routine screening and confirmation to outbreak investigation and epidemiological surveillance.
The market is moving toward faster and more decentralized testing as healthcare providers seek results that can support immediate treatment decisions. Molecular platforms, particularly PCR-based systems, are becoming increasingly important because of their ability to detect pathogens with high analytical sensitivity and specificity.
Next-generation sequencing is also gaining importance for pathogen characterization, genomic surveillance, and identification of emerging infectious organisms. The ability to analyze pathogen genomes can provide valuable information regarding transmission patterns, mutations, antimicrobial resistance, and outbreak evolution.
Point-of-care testing represents another major area of transformation. Portable and easy-to-use diagnostic devices are allowing testing to move beyond conventional laboratories into clinics, emergency departments, pharmacies, community settings, and patients’ homes. This shift can improve access to diagnostics while reducing turnaround times.
Artificial intelligence and data analytics are further enhancing infectious disease diagnostics by supporting automated interpretation, pattern recognition, laboratory workflow optimization, and disease surveillance. Integration of diagnostic data with digital health systems may also improve communication between laboratories, clinicians, and public health authorities.
Key Trends in the Infectious Disease Diagnostics Market
Government Initiatives and Funding
Government programs focused on infectious disease prevention, surveillance, preparedness, and outbreak control are supporting the development and adoption of diagnostic technologies. Public investments in laboratory infrastructure and disease monitoring systems are particularly important in regions where infectious diseases continue to create substantial healthcare and economic burdens.
Government agencies and healthcare organizations are also emphasizing antimicrobial resistance surveillance. Improved diagnostic capabilities can help identify infectious organisms and determine appropriate antimicrobial treatment, supporting efforts to reduce unnecessary antibiotic use.
In March 2025, French diagnostics company bioMérieux received FDA 510(k) clearance for its VITEK COMPACT PRO system. The platform is designed for microorganism identification and antibiotic susceptibility testing, supporting clinical laboratories in infectious disease diagnosis and antimicrobial resistance management.
Advancements in Molecular Diagnostics
Molecular diagnostic technologies are becoming increasingly sophisticated, with PCR, NGS, and emerging technologies such as CRISPR-based diagnostics contributing to faster and more precise pathogen identification. These technologies can detect infectious organisms even when conventional culture-based methods may require considerably more time.
The growing need for early diagnosis during outbreaks is encouraging healthcare providers to invest in molecular testing infrastructure. Multiplex molecular assays are particularly valuable because they can identify multiple pathogens from a single patient sample, supporting differential diagnosis and reducing the need for sequential testing.
In March 2024, SEKISUI Diagnostics received Emergency Use Authorization for its OSOM Flu SARS-CoV-2 Combo Test, enabling testing in professional healthcare and home-testing environments. The development illustrates the broader shift toward accessible and decentralized infectious disease diagnostics.
Market Dynamics
Driver: Rising Prevalence of Infectious Diseases
The increasing incidence of infectious diseases remains one of the strongest growth drivers for the global infectious disease diagnostics market. Viral and bacterial infections continue to affect populations worldwide, generating sustained demand for diagnostic testing across hospitals, clinics, laboratories, and community healthcare settings.
The recurrence of infectious disease outbreaks has reinforced the importance of rapid pathogen identification. Healthcare providers require diagnostic tools that can distinguish between infections with similar symptoms and support appropriate treatment decisions.
Emerging infectious diseases are also increasing the need for flexible diagnostic platforms that can be adapted to detect newly identified pathogens. As disease surveillance becomes more important, governments and healthcare institutions are investing in diagnostic capabilities that can support both routine testing and emergency outbreak response.
Restraint: High Cost of Advanced Diagnostic Tests
The high cost associated with advanced diagnostic technologies remains a key challenge for market expansion. Molecular analyzers, sequencing systems, automated laboratory platforms, specialized reagents, and associated maintenance services can require substantial capital investment.
The cost challenge is particularly significant in low- and middle-income countries, where healthcare facilities may operate with limited budgets and inadequate laboratory infrastructure. In addition to equipment costs, healthcare providers must account for reagent consumption, maintenance, software, training, and skilled personnel.
These financial barriers can limit the adoption of sophisticated diagnostic systems despite increasing clinical demand. Manufacturers are therefore focusing on developing affordable, compact, automated, and scalable diagnostic platforms that can expand access to advanced testing.
Opportunity: Advancements in Molecular and Point-of-Care Technologies
Rapid innovation in molecular and point-of-care diagnostics presents significant growth opportunities for market participants. Modern molecular systems can deliver highly accurate pathogen detection while reducing turnaround time compared with conventional diagnostic approaches.
Point-of-care platforms offer another important opportunity because they enable testing closer to the patient. This is especially valuable in remote areas, emergency departments, outpatient clinics, pharmacies, and other decentralized healthcare environments.
The development of portable molecular analyzers, multiplex assays, rapid antigen tests, and connected diagnostic devices can improve access to infectious disease testing. As healthcare systems increasingly prioritize early diagnosis and rapid treatment, demand for these technologies is expected to increase.
Segmental Insights
Reagents, Kits & Consumables Segment
The reagents, kits, and consumables segment accounted for a leading position in the infectious disease diagnostics market in 2024. These products are essential components of diagnostic workflows and are required repeatedly as testing volumes increase.
The expansion of infectious disease screening, routine testing, outbreak surveillance, and molecular diagnostics directly contributes to recurring demand for reagents and consumables. The increasing adoption of sophisticated testing technologies is also driving demand for specialized assay kits and laboratory supplies.
Unlike capital equipment, many reagents and consumables must be replenished regularly, creating a recurring revenue stream for manufacturers. Increasing testing volumes across hospitals, diagnostic laboratories, and research facilities are therefore expected to sustain demand for this segment.
The instruments segment is expected to register the fastest growth during the forecast period. Increasing demand for automated analyzers, molecular diagnostic systems, microbiology platforms, and POC instruments is encouraging healthcare organizations to modernize their diagnostic infrastructure.
Automation can improve laboratory productivity, reduce manual errors, increase testing capacity, and shorten turnaround times. These benefits are particularly important for healthcare systems managing increasing patient volumes and infectious disease outbreaks.
Immunodiagnostics Segment
The immunodiagnostics segment dominated the infectious disease diagnostics market in 2024, supported by the widespread use of antigen and antibody-based testing methods. These technologies are valued for their relatively simple workflows, rapid results, and suitability for different healthcare environments.
Immunodiagnostic tests are used for detecting immune responses or specific components associated with infectious pathogens. Their applications extend across hospitals, clinical laboratories, physician offices, screening programs, and decentralized testing environments.
The continued need for routine infectious disease screening and early diagnosis is expected to support the segment. The development of improved assays with enhanced sensitivity and specificity may further strengthen adoption.
The molecular diagnostics segment is anticipated to experience the fastest growth during the forecast period. Increasing demand for accurate and rapid pathogen identification is driving the adoption of PCR-based and other molecular testing technologies.
Molecular diagnostics are particularly valuable during outbreaks because they can provide highly specific pathogen detection and support rapid clinical decision-making. Growing investments in molecular testing infrastructure and increasing awareness of early diagnosis are expected to accelerate market penetration.
Laboratory-Based Testing Segment
Laboratory-based testing held the largest share of the infectious disease diagnostics market in 2024. Centralized laboratories remain critical to healthcare systems because they can perform high-volume testing and support complex diagnostic procedures.
These facilities typically have access to sophisticated instruments, specialized personnel, quality-control systems, and established laboratory workflows. They are therefore well positioned to perform confirmatory testing, routine screening, surveillance, and specialized infectious disease analysis.
The continued demand for high-throughput testing and epidemiological surveillance is expected to maintain the importance of laboratory-based diagnostics. However, the market is simultaneously shifting toward decentralized testing as healthcare providers seek faster results.
The point-of-care testing segment is projected to grow rapidly during the forecast period. POC diagnostics provide results closer to the patient and can reduce the time required to initiate appropriate treatment.
Rapid antigen and antibody tests, portable molecular platforms, and other decentralized technologies are increasingly being deployed in clinics, pharmacies, emergency settings, and remote healthcare locations. Growing demand for convenience and rapid diagnosis is expected to accelerate POC adoption.
Respiratory Infections Segment
The respiratory infections segment represented a major application area within the infectious disease diagnostics market in 2024 and is expected to continue expanding. Respiratory infections such as influenza, COVID-19, and respiratory syncytial virus remain significant contributors to global testing demand.
The high incidence and seasonal recurrence of respiratory infections create sustained requirements for rapid diagnostic testing. Healthcare providers need to distinguish between different respiratory pathogens because symptoms can overlap while treatment approaches may differ.
The availability of multiplex molecular tests capable of detecting multiple respiratory pathogens from a single sample is further supporting segment growth. Increasing awareness of early diagnosis and the importance of infection control are expected to reinforce demand for respiratory infection diagnostics.
Hospitals Segment
Hospitals accounted for the largest revenue share of the infectious disease diagnostics market in 2024. Hospitals manage large patient populations and require extensive diagnostic capabilities across emergency departments, intensive care units, inpatient wards, outpatient services, and specialized departments.
The availability of sophisticated diagnostic equipment and trained healthcare professionals enables hospitals to conduct a broad range of infectious disease tests. Rapid diagnosis is particularly important in critically ill patients and suspected outbreak situations where treatment decisions may need to be made quickly.
Hospitals are also central to infection prevention and control programs. Increasing emphasis on early pathogen identification, antimicrobial stewardship, and outbreak management is expected to maintain hospitals as major end users of infectious disease diagnostic technologies.
Diagnostic laboratories are expected to witness lucrative growth during the forecast period. Independent and specialized laboratories provide high-volume testing, advanced analytical capabilities, and specialized infectious disease services for healthcare providers.
The increasing adoption of automated testing platforms is improving laboratory efficiency and throughput. Diagnostic laboratories are also increasingly collaborating with hospitals and other healthcare organizations to provide specialized testing and support disease surveillance.
Competitive Landscape
The infectious disease diagnostics market is characterized by competition among established diagnostic companies, diversified healthcare technology manufacturers, and specialized molecular diagnostics providers. Companies are focusing on product launches, regulatory approvals, technological innovation, strategic collaborations, acquisitions, and expansion of diagnostic portfolios to strengthen their market presence.
Key players are increasingly investing in molecular diagnostics, multiplex testing, automated laboratory systems, rapid diagnostics, antimicrobial susceptibility testing, and integrated digital solutions. The competitive environment is also being influenced by the growing demand for decentralized testing and technologies capable of addressing antimicrobial resistance.
Key Companies Mapped
- F. Hoffmann-La Roche Ltd
- Abbott
- bioMérieux
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- DH Life Sciences, LLC
- BD (Becton, Dickinson and Company)
- Hologic, Inc.
- QIAGEN
- Revvity
- Other prominent regional and emerging diagnostic technology companies
Future Outlook
The infectious disease diagnostics market is expected to maintain steady growth as healthcare systems worldwide place greater emphasis on early detection, disease surveillance, outbreak preparedness, and antimicrobial resistance management. The increasing burden of infectious diseases will continue to generate demand for reliable diagnostic solutions across hospitals, laboratories, clinics, and decentralized healthcare settings.
Molecular diagnostics and point-of-care testing are expected to remain among the most important areas of technological development. Faster molecular platforms, multiplex assays, portable analyzers, and increasingly automated diagnostic workflows can help healthcare providers make faster and more informed decisions.
The integration of artificial intelligence, digital health, cloud-based data management, and connected diagnostic devices is also expected to transform infectious disease testing. These technologies can improve laboratory workflow management, data interpretation, disease surveillance, and communication between diagnostic facilities and healthcare providers.
At the same time, addressing the high cost of advanced diagnostics will remain important for expanding access in resource-constrained markets. Manufacturers that can combine accuracy, speed, portability, automation, and affordability are likely to be well positioned to capture emerging opportunities.
Overall, the combination of rising infectious disease prevalence, increasing antimicrobial resistance concerns, technological innovation, government initiatives, and growing demand for rapid testing is expected to support the continued expansion of the global infectious disease diagnostics market over the next five years.
Download pdf Brochure: https://meditechinsights.com/infectious-disease-diagnostics-market/request-sample/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.